Tumor−associated macrophage polarization in the inflammatory tumor microenvironment

The chronic inflammation of tumor continues to recruit TAMs (tumor−associated macrophages) to the TME (tumor microenvironment) and promote polarization. Pro-inflammatory signals polarize macrophages to the M1 phenotype to enhance inflammation against pathogens. Tumor inflammatory development changes the pro-inflammatory response to an anti-inflammatory response, resulting in the alteration of macrophages from M1 to M2 to promote tumor progression. Additionally, hypoxia activates HIF (hypoxia-inducible factors) in the TME, which reprograms macrophages to the M2 phenotype to support tumor development. Here, we discuss the factors that drive phenotypic changes in TAMs in the inflammatory TME, which will help in the development of cancer immunotherapy of macrophages.

[1]  Zhengqin Gu,et al.  Tumor-associated macrophages promote migration and invasion via modulating IL-6/STAT3 signaling in renal cell carcinoma. , 2022, International immunopharmacology.

[2]  K. Izumi,et al.  Roles of CCL2-CCR2 Axis in the Tumor Microenvironment , 2021, International journal of molecular sciences.

[3]  Lei Wu,et al.  Inflammation and tumor progression: signaling pathways and targeted intervention , 2021, Signal Transduction and Targeted Therapy.

[4]  Sherine F. Elsawa,et al.  Macrophage Polarization States in the Tumor Microenvironment , 2021, International journal of molecular sciences.

[5]  M. Pellegrini,et al.  Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapy , 2021, Nature Communications.

[6]  Y. Zakharia,et al.  Current status of intralesional agents in treatment of malignant melanoma , 2021, Annals of translational medicine.

[7]  A. Patnaik,et al.  Targeting Innate Immunity in Cancer Therapy , 2021, Vaccines.

[8]  Weilin Wang,et al.  The Role of Tumor Associated Macrophages in Hepatocellular Carcinoma , 2021, Journal of Cancer.

[9]  B. Hou,et al.  Erratum: Macrophages activating chemokine (C-X-C motif) ligand 8/miR-17 cluster modulate hepatocellular carcinoma cell growth and metastasis. , 2021, American journal of translational research.

[10]  Pingping Shen,et al.  Targeting tumor-associated macrophages as an antitumor strategy. , 2020, Biochemical pharmacology.

[11]  Ting Zhang,et al.  Tumor-Associated Macrophages in Tumor Immunity , 2020, Frontiers in Immunology.

[12]  W. Park,et al.  Tumor-promoting macrophages prevail in malignant ascites of advanced gastric cancer , 2020, Experimental & Molecular Medicine.

[13]  Ting Huang,et al.  Targeting tumor‐associated macrophages: A potential treatment for solid tumors , 2020, Journal of cellular physiology.

[14]  J. Kzhyshkowska,et al.  Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers , 2020, Frontiers in Oncology.

[15]  Zhen Chen,et al.  Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment. , 2020, International immunopharmacology.

[16]  Baojun Liu,et al.  Tumor-associated macrophages in lung cancer: Friend or foe? , 2020, Molecular medicine reports.

[17]  Rodolfo Daniel Cervantes-Villagrana,et al.  Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies , 2020, Signal Transduction and Targeted Therapy.

[18]  R. Jiang,et al.  IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma , 2020, Journal for immunotherapy of cancer.

[19]  Q. Hao,et al.  CCL2/CCR2 signaling in cancer pathogenesis , 2020, Cell Communication and Signaling.

[20]  Martha E. Zeeman,et al.  Human chimeric antigen receptor macrophages for cancer immunotherapy , 2020, Nature Biotechnology.

[21]  J. Ryu,et al.  IL-6 produced by prostate epithelial cells stimulated with Trichomonas vaginalis promotes proliferation of prostate cancer cells by inducing M2 polarization of THP-1-derived macrophages , 2020, PLoS neglected tropical diseases.

[22]  Qianming Chen,et al.  RACK1 promotes cancer progression by increasing the M2/M1 macrophage ratio via the NF‐κB pathway in oral squamous cell carcinoma , 2020, Molecular oncology.

[23]  Qiaojun He,et al.  Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses , 2019, Acta pharmaceutica Sinica. B.

[24]  Yibing Chen,et al.  Tumor-associated macrophages: an accomplice in solid tumor progression , 2019, Journal of Biomedical Science.

[25]  Pingping Shen,et al.  Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix , 2019, British Journal of Cancer.

[26]  S. Beer-Hammer,et al.  Function, Regulation and Biological Roles of PI3Kγ Variants , 2019, Biomolecules.

[27]  D. Stolz,et al.  Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8+ T Cell-Derived Interferon-γ. , 2019, Immunity.

[28]  M. Turner,et al.  Membrane Cholesterol Efflux Drives Tumor-Associated Macrophage Reprogramming and Tumor Progression. , 2019, Cell metabolism.

[29]  C. Ries,et al.  Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response , 2019, Nature Cell Biology.

[30]  Min Young Yoo,et al.  Tumor-Associated Macrophages Enhance Tumor Hypoxia and Aerobic Glycolysis. , 2019, Cancer research.

[31]  S. M. Hassanian,et al.  PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[32]  Xiaoyun Lu,et al.  Small-Molecule CSF1R Inhibitors as Anticancer Agents. , 2019, Current medicinal chemistry.

[33]  Jiao Guo,et al.  M2b macrophage polarization and its roles in diseases , 2018, Journal of leukocyte biology.

[34]  I. Weissman,et al.  CD47 Blockade by Hu5F9‐G4 and Rituximab in Non‐Hodgkin's Lymphoma , 2018, The New England journal of medicine.

[35]  J. Pollard,et al.  Targeting macrophages: therapeutic approaches in cancer , 2018, Nature Reviews Drug Discovery.

[36]  I. Manabe,et al.  Macrophages in inflammation, repair and regeneration , 2018, International immunology.

[37]  R. Fields,et al.  Recruitment of CCR2+ tumor associated macrophage to sites of liver metastasis confers a poor prognosis in human colorectal cancer , 2018, Oncoimmunology.

[38]  D. Laouini,et al.  Role of Human Macrophage Polarization in Inflammation during Infectious Diseases , 2018, International journal of molecular sciences.

[39]  Jennifer R. Grandis,et al.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer , 2018, Nature Reviews Clinical Oncology.

[40]  M. Fu,et al.  Polarizing Macrophages In Vitro. , 2018, Methods in molecular biology.

[41]  Kathryn Prame Kumar,et al.  Partners in crime: neutrophils and monocytes/macrophages in inflammation and disease , 2018, Cell and Tissue Research.

[42]  Victor G. Martinez,et al.  BMP4 Induces M2 Macrophage Polarization and Favors Tumor Progression in Bladder Cancer , 2017, Clinical Cancer Research.

[43]  B. Brüne,et al.  Cancer cell and macrophage cross‐talk in the tumor microenvironment , 2017, Current opinion in pharmacology.

[44]  C. Ries,et al.  Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy , 2017, Journal of Immunotherapy for Cancer.

[45]  Jung-Joon Min,et al.  Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin , 2017, Science Translational Medicine.

[46]  Alberto Mantovani,et al.  Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.

[47]  B. Hou,et al.  Macrophages activating chemokine (C-X-C motif) ligand 8/miR-17 cluster modulate hepatocellular carcinoma cell growth and metastasis. , 2017, American journal of translational research.

[48]  Philippe Foubert,et al.  PI3Kγ is a molecular switch that controls immune suppression , 2016, Nature.

[49]  S. Trudel,et al.  TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding , 2016, Clinical Cancer Research.

[50]  S. Haferkamp,et al.  LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. , 2016, Cell metabolism.

[51]  M. Mazzone,et al.  The impact of hypoxia on tumor-associated macrophages. , 2016, The Journal of clinical investigation.

[52]  A. V. Nguyen,et al.  Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression. , 2016, Cancer discovery.

[53]  L. French,et al.  Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophages , 2016, Scientific Reports.

[54]  Jedd D. Wolchok,et al.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations , 2016, Science Translational Medicine.

[55]  A. V. Nguyen,et al.  Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer. , 2016, Cancer discovery.

[56]  S. Hanash,et al.  EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. , 2016, Cancer research.

[57]  D. Kuang,et al.  Chemokine (C‐X‐C motif) receptor 3–positive B cells link interleukin‐17 inflammation to protumorigenic macrophage polarization in human hepatocellular carcinoma , 2015, Hepatology.

[58]  B. Shen,et al.  Long noncoding RNA lncTCF7, induced by IL-6/STAT3 transactivation, promotes hepatocellular carcinoma aggressiveness through epithelial-mesenchymal transition , 2015, Journal of experimental & clinical cancer research : CR.

[59]  M. Roussel,et al.  TNF Counterbalances the Emergence of M2 Tumor Macrophages. , 2015, Cell reports.

[60]  I. Keklikoglou,et al.  Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. , 2015, Cancer research.

[61]  S. Fan,et al.  Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma. , 2015, Journal of hepatology.

[62]  Yong-sheng Xiao,et al.  Macrophage-secreted IL-8 induces epithelial-mesenchymal transition in hepatocellular carcinoma cells by activating the JAK2/STAT3/Snail pathway. , 2015, International journal of oncology.

[63]  Vivien W. Chan,et al.  Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. , 2014, Cancer cell.

[64]  K. Mertz,et al.  Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis , 2014, Nature.

[65]  K. Tracey,et al.  HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells. , 2014, Cancer research.

[66]  Francois Moisan,et al.  Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers , 2014, Molecular oncology.

[67]  Toshio Tanaka,et al.  IL-6 in inflammation, immunity, and disease. , 2014, Cold Spring Harbor perspectives in biology.

[68]  A. Ben-Baruch,et al.  The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer. , 2014, Cancer letters.

[69]  G. Cline,et al.  Functional polarization of tumour-associated macrophages by tumour-derived lactic acid , 2014, Nature.

[70]  Jeffrey W Pollard,et al.  Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.

[71]  Diana Boraschi,et al.  MafB is a downstream target of the IL-10/STAT3 signaling pathway, involved in the regulation of macrophage de-activation. , 2014, Biochimica et biophysica acta.

[72]  S. Bhattacharyya,et al.  FoxP3 acts as a cotranscription factor with STAT3 in tumor-induced regulatory T cells. , 2013, Immunity.

[73]  P. Xie,et al.  M2-polarized tumor-associated macrophages promoted epithelial–mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway , 2013, Laboratory Investigation.

[74]  B. Brüne,et al.  Hypoxia-inducible factor (HIF) in hormone signaling during health and disease. , 2013, Cardiovascular & hematological agents in medicinal chemistry.

[75]  R. Kaur,et al.  Gliomas Promote Immunosuppression through Induction of B7-H1 Expression in Tumor-Associated Macrophages , 2013, Clinical Cancer Research.

[76]  A. Tessitore,et al.  The Inflammatory Microenvironment in Hepatocellular Carcinoma: A Pivotal Role for Tumor-Associated Macrophages , 2012, BioMed research international.

[77]  K. Pienta,et al.  Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer , 2013, Investigational New Drugs.

[78]  Marco Manca,et al.  Distribution of macrophage polarization markers in human atherosclerosis. , 2012, Atherosclerosis.

[79]  D. Hume,et al.  Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. , 2012, Blood.

[80]  Sherine F. Elsawa,et al.  Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity. , 2011, Blood.

[81]  T. Wynn,et al.  Protective and pathogenic functions of macrophage subsets , 2011, Nature Reviews Immunology.

[82]  P. Foubert,et al.  Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression. , 2011, Cancer cell.

[83]  W. Pan,et al.  Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients , 2009, International journal of cancer.

[84]  A. Waisman,et al.  A transgenic mouse model of inducible macrophage depletion: effects of diphtheria toxin-driven lysozyme M-specific cell lineage ablation on wound inflammatory, angiogenic, and contractive processes. , 2009, The American journal of pathology.

[85]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[86]  W. Lichtenegger,et al.  Monitoring of IL-10 in the serum of patients with advanced ovarian cancer: results from a prospective pilot-study. , 2009, Cytokine.

[87]  G. Invernici,et al.  Transforming growth factor-beta1 and CD105 promote the migration of hepatocellular carcinoma-derived endothelium. , 2008, Cancer research.

[88]  Zhao-You Tang,et al.  High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  P. Allavena,et al.  The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. , 2008, Critical reviews in oncology/hematology.

[90]  Jiasen Cheng,et al.  Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. , 2007, Blood.

[91]  C. Chiang,et al.  Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth. , 2007, International journal of radiation oncology, biology, physics.

[92]  A. Sica,et al.  Altered macrophage differentiation and immune dysfunction in tumor development. , 2007, The Journal of clinical investigation.

[93]  S. Gordon,et al.  Ovarian Cancer Cells Polarize Macrophages Toward A Tumor-Associated Phenotype1 , 2006, The Journal of Immunology.

[94]  Kazuo Kobayashi,et al.  Macrophages in inflammation. , 2005, Current drug targets. Inflammation and allergy.

[95]  John A Kellum,et al.  Lactic and hydrochloric acids induce different patterns of inflammatory response in LPS-stimulated RAW 264.7 cells. , 2004, American journal of physiology. Regulatory, integrative and comparative physiology.

[96]  Silvano Sozzani,et al.  Central role for G protein-coupled phosphoinositide 3-kinase γ in inflammation , 2000 .

[97]  M. Bally,et al.  The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors. , 1997, The Journal of pharmacology and experimental therapeutics.